State Street(R) Health Care Select Sector SPDR(R) ETF
SELECT SECTOR SPDR TRUST · Series S000006412 · 1 share classes
data updated 2026-09-08
Fund profile
As filed in the prospectus · 2026 Q1
State Street Health Care Select Sector SPDR ETF (the Fund) seeks to provide investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in the Health Care Select Sector Index (the Index).
The fund holds substantially all securities in the Health Care Select Sector Index, a modified market-capitalization-weighted index of 60 large-cap health care stocks drawn from the S&P 500, tracking it through full replication. The fund invests at least 95% of assets in index constituents, with the remainder in cash and money market instruments. Because the fund holds all index securities in fixed weights, its performance will track the index before expenses.
| Share class | Expense ratio |
|---|---|
| XLV | 0.08% |
Portfolio turnover 2.00% · as of 2026 Q1
Allocation
Asset groups · long / short shown separately, never netted · 2026 Q2
| Stocks | 99.68% |
| Cash & short-term | 0.26% |
| Derivatives | 0.01% |
Derivatives are shown at market value, not notional exposure.
Latest quarter
What changed since the fund's previous filing
New: VEEV, Chicago Mercantile Exchange, CONTRA HOLOGIC INCORPO
Exited: Hologic Inc, Chicago Mercantile Exchange
Return profile
Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026
May 2026 and Jun 2026 have been filed since the trailing figures were struck, so they are not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
Holdings
By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page
| Ticker | Issuer | %NAV | Reported price | Value | Shares |
|---|---|---|---|---|---|
| LLY | Eli Lilly & CoLLY | 16.51% | $1,199.43 | $6.70B | 5.6M |
| JNJ | Johnson & JohnsonJNJ | 10.64% | $253.97 | $4.32B | 17.0M |
| ABBV | AbbVie IncABBV | 7.74% | $251.64 | $3.14B | 12.5M |
| UNH | UnitedHealth Group IncUNH | 6.57% | $415.63 | $2.67B | 6.4M |
| MRK | Merck & Co IncMRK | 5.52% | $128.50 | $2.24B | 17.4M |
| AMGN | Amgen IncAMGN | 3.40% | $362.12 | $1.38B | 3.8M |
| TMO | Thermo Fisher Scientific IncTMO | 3.24% | $501.36 | $1.32B | 2.6M |
| ABT | Abbott LaboratoriesABT | 2.75% | $90.74 | $1.12B | 12.3M |
| GILD | Gilead Sciences IncGILD | 2.73% | $126.34 | $1.11B | 8.8M |
| ISRG | Intuitive Surgical IncISRG | 2.45% | $397.68 | $995.03M | 2.5M |
Reported price is the fund's own reported value divided by its own reported shares at 2026-06-30 — not a live quote, and not what the fund paid.
Top 10 positions are 61.55% of net assets, top 25 85.68%, across 62 issuers.
See more of this fund's book
More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.
Sign in free